Background: Positive selection of CD34+ cells may be associated with an alteration of the target cells by antigen-antibody interactions and/or a selection of distinct CD34-cell subgroups within the purified cell fraction. Thus, a negative CD34 cell selection procedure (StemSep™), carried out on leukapheresis samples (LA) of patients with breast cancer (n = 6) or other malignancies (n = 4) was evaluated. Material and Methods:3 samples per patient (each 1 ml) containing 1 ×108 leukocytes (median 3.3% (range 0.9–9.4%) CD34+ cells), were processed as follows: set A CD34+ cell selection alone; set B CD34+ cell selection with concomitant breast cancer cell purging; or set C CD34+ cell selection followed by breast cancer cell purging. The samples of sets B and C were spiked with 1% MCF-7 breast cancer cells. Furthermore, the antibodies included in the breast cancer purging cocktail were evaluated regarding sensitivity and specificity by means of flow cytometry and immunocytochemistry. Results: In the first 2 procedures (sets A/B) the median CD34 cell yield was 49% (range 24–90%), resulting in a CD34 cell purity of 72% (range 32–95%) and in a 3 log reduction of the other cells. The sequential procedure (set C) caused significantly (p < 0.005) higher CD34+ cell losses (16% yield, 81% purity) with a nonsignificantly higher depletion of the other cell types. The selection caused no changes in CD34+ cell clonogenicity for CFU-GM/BFU-E and no loss of viability (>90%). Both simultaneous and sequential selection achieved a tumor cell reduction of more than 3 orders of magnitude (>3 log depletion) whereby APAAP and quantitative RT-PCR for CK19 showed corresponding results in 80% of all samples. Only 2 (4A6 and 5E11) of the 5 tested epithelial breast cancer antibodies showed a binding to MCF-7 and BT-474 cells comparable to the anti-cytokeratin antibody Cam5.2. Conclusions: The negative CD34 cell selection approach investigated in combination with simultaneous specific tumor cell depletion is comparable to other small-scale devices while the sequential procedure had unacceptable CD34 cell losses.

This content is only available via PDF.
© 2001 S. Karger GmbH, Freiburg
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.